Newsletters and Deep Dive digital magazine
Pfizer has selected the first drug candidate from a collaboration with Sosei Group to develop drugs for major diseases, which are aimed at targets from the G protein-coupled receptor (GPCR)
Sosei has announced that its founder and former CEO Shinichi Tamura will be re-taking the position of CEO as of next year.
Allergan and Sosei’s experimental Alzheimer’s medicine has run into trouble – the companies have called a halt to trials after an unexpected toxicology finding in an animal study.<
Troubled generics giant Teva is continuing the heavy pruning of its business and has cut a novel migraine drug from its pipeline.
Drug is first new echinocandin to be approved for marketing in the US in more than a decade.
An inside guide to unlocking clinical research in the UK